GlassScriptPhysician profile
Vikki M Mckinnie
NPI 1548260821
$2,611.76
in general payments reported to CMS, 2019-2025
30 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $264 · 2021: $423 · 2022: $275 · 2023: $458 · 2024: $469 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.06 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $633.49 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $408.98 | 2019-2025 | Aptima, Coolseal Generator, Acessa Provu System |
| Abbvie INC. | $393.29 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.16 | 2019-2025 | |
| Gynesonics, INC. | $160.58 | 2021 | |
| Ethicon US, LLC | $106.90 | 2019-2023 | Vistaseal, Dermabond |
| Roche Diagnostics Corporation | $81.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $77.00 | 2019-2022 | |
| Organon LLC | $62.15 | 2022-2025 | Jada System, Nexplanon |
| Lupin INC. | $50.48 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $36.36 | 2023 | |
| Therapeuticsmd, INC. | $35.88 | 2021-2022 | |
| Cgg Medical INC | $35.83 | 2025 | |
| Duchesnay USA Incorporated | $25.53 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.95 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $24.76 | 2025 | Quikclot |
| Boston Scientific Corporation | $24.35 | 2025 | Axonics |
| Sage Therapeutics, LLC | $20.61 | 2024 | |
| Pfizer INC. | $18.94 | 2024 | |
| Sumitomo Pharma America, INC. | $17.48 | 2023 | Gemtesa |
| Olympus America INC. | $16.68 | 2021 | |
| Medtronic, INC. | $15.60 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.11 | 2019 | |
| Davol INC. | $14.96 | 2019 | |
| Coopersurgical, INC. | $14.93 | 2022 | |
| Millicent US INC | $14.90 | 2025 | Intrarosa, Femlyv |
| Allergan, INC. | $12.63 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.99 | 2020 | |
| Covidien LP | $11.89 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikki Mckinnie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.